ArticleThe journal of headache and pain2020
Headache medication and the COVID-19 pandemic.
Article in The journal of headache and pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Prevalence of NSAID use among people with COVID-19 and the association with COVID-19-related outcomes: Systematic review and meta-analysis.British journal of clinical pharmacology · 2022Pooled it
- Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.The journal of headache and pain · 2022Pooled it
- Guideline
- Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19.Infection & chemotherapy · 2025Review
- Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.Infection & chemotherapy · 2024Review
- [Subtle and subclinical neurological findings in patients with SARS-CoV-2].Revista medica del Instituto Mexicano del Seguro Social · 2023Observational
- Results of a Web-Based Survey on 2105 Greek Migraine Patients-Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients' Reported Satisfaction.Medicina (Kaunas, Lithuania) · 2022Article
- Post-COVID Headache: A Literature Review.Current pain and headache reports · 2022Review
- COVID-19 neuropsychiatric repercussions: Current evidence on the subject.World journal of methodology · 2022Review
- Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.Infection & chemotherapy · 2022Review
- Neurological toll of COVID-19.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Article
- Persistent headache after COVID-19: Pathophysioloy, clinic and treatment.Neurology perspectives · 2021Review
- Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research.Current pain and headache reports · 2021Review
- Navigating migraine care through the COVID-19 pandemic: an update.Journal of neurology · 2021Article
- Frequency and phenotype of headache in covid-19: a study of 2194 patients.Scientific reports · 2021Observational
- Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary.The journal of headache and pain · 2021Article
- Clinical and diagnostic value of the combination of lymphocyte count and creatine kinase in the detection of coronavirus 2019.Experimental and therapeutic medicine · 2021Article
- Chronic Pain Management during the Covid-19 Pandemic: A Scoping Review.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2021Article
- Renal Manifestations of Covid-19: Physiology and Pathophysiology.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.